What’s behind EU’s skepticism of Bayer-Monsanto merger?

Bayer Monsanto

[Bayer’s acquisition of Monsanto] may not go through. Multiple media outlets have reported that European Union regulators are skeptical of the merger. Why?

One’s initial impulse might be that the EU simply doesn’t like GMOs (which is true), so it will make an example of Monsanto by blocking its acquisition by Bayer. But that doesn’t appear to be the case. According to the Wall Street Journal, the EU approved mergers between DuPont and Dow Chemical as well as Syngenta and ChemChina, albeit after various concessions were made. (Both DuPont and Syngenta sell GMOs.)

Neither does it appear as if the EU is trying to undermine the success of an American business. DuPont and Dow are both headquartered in the U.S.

On the contrary, EU regulators seem to be legitimately concerned about the impact the merger may have on competition.

If the EU is not distracted by politics and anti-GMO activists — and if it is able to focus solely on the economic pros and cons of a merger — it is engaging in appropriate regulatory oversight. But that’s a big “if.”

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion and analysis. Read full, original post: Why Would The EU Put The Kabash On Bayer’s Acquisition Of Monsanto?

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

ChatGPT-Image-May-7-2026-12_32_36-PM
Viewpoint: The state of U.S. vaccine policy? Dismal nationally, but some states are stepping up.
Screenshot-2026-04-13-at-1.39.26-PM
Viewpoint: ‘Safer for children?’ Stonyfield yogurt under fire for deceptive organic marketing
Screenshot-2026-04-22-at-10.46.29-AM
Viewpoint: How to counter science disinformation? Science journalist offers 12 practical tips
ChatGPT-Image-May-7-2026-12_16_37-PM-2
Viewpoint: Are cancer rates ‘skyrocketing’ as RFK, Jr. and MAHA claim? The evidence says mostly the opposite
the magic of mRNA
Viewpoint: Anti-vax fake ‘turbo cancer’ claims threaten cancer treatment breakthroughs
ChatGPT-Image-May-7-2026-01_23_27-PM-2
Viewpoint: Will AI democratize personalized cancer treatment or fuel medical misinformation?
Defense_Secretary_Ash_Carter_tours_the_Microsoft_Cybercrime_Center_in_Seattle_March_3_2016
How criminals are using AI to target social media users and steal their money and confidential data
ChatGPT-Image-May-12-2026-08_39_41-PM
GLP podcast: Big Pharma, Big Ag, Big Food—health harming industries or life-saving innovators?
artificial intelligence brain think illustration md
Viewpoint — Digital gods and human extinction: Will we be the first species ever to design our own descendants?
RFKjr-Tech-Vax-Misinfo
As U.S. officials spread medical misinformation, scientists fact check online
Picture1-1
Cooling the planet with balloons: Could a geoengineering gamble slow global warming?
Screenshot-2026-04-23-at-11.00.36-AM
Regulators' dilemma: Thalidomide, Metformin, and the cost of getting drug approvals wrong
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.